Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have received a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $15.60.

KLRS has been the topic of several analyst reports. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, June 14th. Wedbush assumed coverage on shares of Kalaris Therapeutics in a report on Thursday, May 14th. They issued an “outperform” rating and a $17.00 price objective for the company. Citizens Jmp cut their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 13th. TD Cowen assumed coverage on shares of Kalaris Therapeutics in a research note on Monday, June 15th. They set a “buy” rating on the stock. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th.

Kalaris Therapeutics Stock Performance

Shares of Kalaris Therapeutics stock opened at $4.38 on Friday. Kalaris Therapeutics has a one year low of $2.14 and a one year high of $11.88. The company has a market cap of $104.21 million, a price-to-earnings ratio of -2.04 and a beta of 0.19. The business’s 50 day moving average price is $4.64 and its 200 day moving average price is $6.86.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. On average, analysts predict that Kalaris Therapeutics will post -2 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kalaris Therapeutics news, Director Srinivas Akkaraju bought 244,300 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $4.83 per share, with a total value of $1,179,969.00. Following the completion of the purchase, the director directly owned 2,224,147 shares in the company, valued at $10,742,630.01. The trade was a 12.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 68.10% of the company’s stock.

Institutional Trading of Kalaris Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. WealthTrust Asset Management LLC acquired a new position in Kalaris Therapeutics in the first quarter valued at about $72,000. Simplify Asset Management Inc. raised its stake in shares of Kalaris Therapeutics by 335.5% in the 1st quarter. Simplify Asset Management Inc. now owns 87,426 shares of the company’s stock valued at $504,000 after acquiring an additional 67,352 shares during the period. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics in the 4th quarter worth approximately $92,000. Ikarian Capital LLC acquired a new position in shares of Kalaris Therapeutics in the 4th quarter worth approximately $3,038,000. Finally, RTW Investments LP purchased a new position in shares of Kalaris Therapeutics during the 4th quarter worth approximately $10,972,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.